ClinicalTrials.gg
Enrolling by invitationNCT06541275Updated Aug 9, 2024

Reduction in Volume and Prolonged Shrinkage of Brain Aneurysms After Combined Endovascular Interventions

An observational study in Brain Aneurysm, sponsored by National Centre for Neurosurgery, Republic of Kazakhstan. Enrolling by invitation at 1 site in Kazakhstan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-09.

Sponsored by National Centre for Neurosurgery, Republic of Kazakhstan · Observational

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 5 months ago, but the record still lists the study as enrolling by invitation.
Study type
Observational
Model
Case-only
Time perspective
Other
Enrollment
102
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this observational study is to learn about the long-term effects of combined endovascular interventions in participants over the age of 18 who take endovascular interventions employing endoluminal flow diverter stents, with or without coils, and a hybrid approach of combining bypass anastomosis and parent artery occlusion using the endovascular method to treat their giant symptomatic intracranial aneurysms. The main question it aims to answer is:

  • How does the methods of endovascular intervention chosen affect the value of the aneurysmal sac shrinkage and volume reduction? Participants underwent endovascular intervention at the hospital will be recruited with further follow-up of 6, 12, and 24 months.
Read the detailed description

Large (with a diameter of ≥15 mm) and giant (with a diameter of ≥25 mm) intracranial aneurysms represent a distinct subset within the spectrum of cerebral aneurysms, necessitating intricate treatment considerations given their challenging nature and unfavorable natural course. Traditionally characterized by gradual enlargement, these aneurysms frequently progress to rupture, leading to substantial morbidity and higher mortality rates. Additionally, these aneurysms commonly induce peri-aneurysmal edematous changes in the neighboring brain regions. This impact extends to cranial nerves, potentially resulting in functional compromise due to compression of the surrounding brain tissue. The degree of functional impairment is contingent upon the distribution of the cranial nerves within the cerebral circulation.Current treatment options for large and giant cerebral aneurysms involve endovascular interventions employing endoluminal flow diverter stents, with or without coils, and a hybrid approach of combining bypass anastomosis and parent artery occlusion using the endovascular method. These methods have consistently demonstrated high rates of complete aneurysm occlusion and maintain an acceptable safety profile.

  1. Previous studies at the National Centre for Neurosurgery. "Management of giant internal carotid aneurysm by extracranial-intracranial bypass and flow diverter stent" and "Early and midterm results of treatment of giant internal carotid artery paraclinoid aneurysms with trapping and flow diverters" has previously been studied and published. The studies included patients who underwent treatment at the Vascular and Functional Neurosurgery Department, National Centre for Neurosurgery, Astana, Kazakhstan.
  1. Research Gap and Novelty of a Research Project. Despite the favorable outcomes observed with treatment methods such as endovascular interventions employing endoluminal flow diverter stents, either with or without coils, and a hybrid approach involving bypass anastomosis and parent artery occlusion using the endovascular method, there is a notable lack of comprehensive data on aneurysmal sac shrinkage and complete obliteration rates following these treatments. To address this gap, this study will evaluate the treatment effects specifically on aneurysmal sac shrinkage and volume reduction - crucial factors for a comprehensive assessment of the effectiveness of these interventions.

In parallel, other studies have delved into investigating aneurysm shrinkage following the use of flow diverters with and without coils. Nevertheless, it is crucial to emphasize that these studies failed to take into account the extent of aneurysm closure evaluated using the Raymond Roy scale, as well as data on the deployment of stents assessed using the O'Kelly-Marotta grading system. Additionally, most of the publications are limited to case descriptions only. Notably, these cases did not include an examination of the packing density of the aneurysm. Furthermore, there is a lack of evidence regarding the role of inflammatory factors in the reduction of brain aneurysms following the deployment of flow diverters. In contrast, studies on patients with abdominal aortic aneurysms have explored the influence of preoperative inflammatory markers, such as Neutrophil-to-Lymphocyte (NLR) and Platelet-to-Lymphocyte (PLR) ratios, on post-endovascular aneurysm repair (EVAR) sac shrinkage. These studies have underscored the substantial impact of these inflammatory markers on aneurysm shrinkage following stent placement. Consequently, this prompts consideration for potential research on these variables in cerebral vascular aneurysm model studies.

In summary, while the flow-diverter treatment process typically spans 6 months to a year with the objective of complete aneurysm elimination, there remains a significant lack of data regarding the extended clinical outcomes of flow-diverter therapy, particularly in the context of large-thrombosed aneurysms.

Study Design. Combined Retrospective-Prospective Study.

Primary Objectives. This study will assess the dynamic reduction in volume and prolonged shrinkage of giant and symptomatic cerebral aneurysms following endovascular interventions employing endoluminal flow diverter stents, with or without coils, and a hybrid approach of combining bypass anastomosis and parent artery occlusion using the endovascular methods.

Objectives:

  1. Patient Group Formation:

    Retrospective study:

    • analyze the medical records and form a database for further follow-up.

    Prospective study:

    • Form a group of patients who meet the inclusion criteria.
    • Conduct/study MRI/CT, cerebral angiography, and endovascular techniques to confirm the large and giant intracranial aneurysms.
  2. Analyze the results:

    • Conduct a detailed analysis and interpretation of the results obtained from selective cerebral angiography and MRA post-surgery.
    • Follow-up every 6 to 12 months.
    • In the endovascular group, categorize aneurysm occlusion using the O'Kelly-Marotta (OKM) grading scale during the procedure.
  3. Long-term Outcome Study:

    • Study the long-term results for patients who underwent surgical intervention.
    • Identify factors influencing aneurysmal sac shrinkage and volume reduction.
    • Examine clinical outcomes, considering the type and volume of the surgical intervention.
  4. Criteria Development:

    • Develop criteria for selecting the most appropriate type of surgical intervention for patients with large and giant aneurysms.
    • Improve overall treatment efficacy and enhance surgical outcomes based on comprehensive evaluations and long-term observations.

Patietn Safety. The treatment of patients is performed in a hospital accredited by the Joint Commission International by certified neurosurgeons, and using FDA-approved intraoperative devices. The hospital strictly adheres to all national treatment protocols.

Statistical Method. Excel (Microsoft Office) will be used for cleaning and coding the data. Statistical analysis will be performed on Stata statistical software (Stata Corp.). Descriptive data analysis will include reporting of frequencies and/or percentages where applicable. The normal distribution of continuous data will be checked using histograms and scatter plots. Normally distributed continuous variables will be presented as means ± SD, categorical variables will be presented as percentages. Appropriate statistical tests will be used depending on the variables and sample. Outcomes will be tested for association between continuous and categorical variables with Student's t-test, and/or one-way analysis of variance (ANOVA), and/or Wilcoxon signed-rank test, where appropriate. Chi-square test will be used for categorical variables. A p-value of less than 0.05 will be considered statistically significant. Further statistics will be applied where appropriate.

Sample size: The number of patients with a diagnosis of "large and giant intracranial aneurysms" admitted to the Department of Vascular and Functional Neurosurgery at the National Centre for Neurosurgery and underwent endovascular intervention is approximately 15 patients per year. The sample for the retrospective study will be approximately 75 patients. For the prospective study, the sample size calculation with a 95% confidence interval and a power value of 80% resulted in a total of 22 patients. The required sample size will be increased to 27 to account for a potential 20% failure rate in follow-up lost participants. Sample size calculations have been done using OpenEpi.

02

Conditions studied

  • Brain Aneurysm

Browse trials for

Keywords

  • brain aneurysm
  • endovascular flow diverters
  • neurovascular
03

In context

Intracranial Aneurysm

418 studies on the registry are indexed under Intracranial Aneurysm; 119 are open to participants now.

This study's planned enrollment of 102 is below the median of 200 across 191 observational studies indexed under Intracranial Aneurysm.

Browse Intracranial Aneurysm studies →

Lead sponsor

National Centre for Neurosurgery, Republic of Kazakhstan is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Study population involves participants who were treated at the Vascular and Functional Neurosurgery Department of the National Centre for Neurosurgery in Astana, Kazahstan.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants aged 18 years and older;
  • Participants with large and giant intracranial aneurysms and underwent endovascular interventions within the last 5 years (2019-2023).

Exclusion criteria

Exclusion Criteria:

  • Participants under the age of 18;
  • Participants with small intracranial aneurysms in the anamnesis and underwent microsurgery.
05

Study design

Observational model
Case-only
Time perspective
Other
Enrollment
102 participants (estimated)
Patient registry
No

Interventions

  • Diagnostic testbrain MRI and CT

    The diagnostic tests will be conducted at 6, 12, and 24 months of follow-up.

06

What researchers measure

Primary outcomes

  1. A value of the aneurysmal sac shrinkage and volume reduction

    A detailed analysis and interpretation of the results obtained from selective cerebral angiography and MRA post-surgery at 6, 12, and 24 months will be performed on participants who underwent endovascular interventions for giant symptomatic brain aneurysms. The analysis will assess the dynamic volume reduction and sac shrinkage.

    Time frame: From enrollment to the further follow-up of 6, 12, and 24 months.

07

Study locations

1 site
08

References and documents

Publications

  • Pasqui E, de Donato G, Molino C, Abu Leil M, Anzaldi MG, Galzerano G, Palasciano G. Residual Aneurysmal Sac Shrinkage Post-Endovascular Aneurysm Repair: The Role of Preoperative Inflammatory Markers. Biomedicines. 2023 Jul 6;11(7):1920. doi: 10.3390/biomedicines11071920. PubMed 37509562 ↗
  • Mitsui T, Nakagawa I, Kotsugi M, Park H, Yokoyama S, Myouchin K, Nakase H. Remarkable shrinkage of a thrombosed giant aneurysm by stent-assisted jam-packed coil embolization. Surg Neurol Int. 2021 Jul 6;12:328. doi: 10.25259/SNI_511_2021. eCollection 2021. PubMed 34345469 ↗
  • Akiyama R, Ishii A, Kikuchi T, Okawa M, Yamao Y, Abekura Y, Ono I, Sasaki N, Tsuji H, Matsukawa S, Miyamoto S. Predictors of aneurysm shrinkage after flow diversion treatment for internal carotid artery aneurysms: quantitative volume analysis with MRI. Front Neurol. 2023 Dec 21;14:1266460. doi: 10.3389/fneur.2023.1266460. eCollection 2023. PubMed 38187156 ↗
  • Makhambetov Y, Kaliyev A, Kikuta KI, Smagulov F, Medetov Y, Kulmirzayev M, Kerimbayev T, Kissamedenov N, Tursynkhan A, Doskaliyev A, Akshulakov S. Early and midterm results of treatment of giant internal carotid artery paraclinoid aneurysms with trapping and flow diverters. Acta Neurochir (Wien). 2019 Sep;161(9):1755-1761. doi: 10.1007/s00701-019-04002-3. Epub 2019 Jul 15. PubMed 31309305 ↗
  • Kaliyev A, Makhambetov Y, Medetov Y, Kulmirzayev M, Dusembayev S, Nurimanov C, Kunakbayev B, Akshulakov S. Management of giant internal carotid aneurysm by extracranial-intracranial bypass and flow diverter stent. Br J Neurosurg. 2023 Dec;37(6):1893-1897. doi: 10.1080/02688697.2021.1947974. Epub 2021 Jul 8. PubMed 34236251 ↗
  • Dutta G, Singh D, Jagetia A, Srivastava AK, Singh H, Kumar A. Endovascular management of large and giant intracranial aneurysms: Experience from a tertiary care neurosurgery institute in India. J Cerebrovasc Endovasc Neurosurg. 2021 Jun;23(2):99-107. doi: 10.7461/jcen.2021.E2020.08.008. Epub 2021 May 17. PubMed 33993689 ↗
  • Lawton MT, Spetzler RF. Surgical management of giant intracranial aneurysms: experience with 171 patients. Clin Neurosurg. 1995;42:245-66. PubMed 8846596 ↗
  • Moon E, Park W, Song Y, Lee DH, Ahn JS, Park JC. Mass Effect After Flow Diversion for Unruptured Large and Giant Cavernous or Paraclinoid Internal Carotid Artery Aneurysm. World Neurosurg. 2023 Dec;180:e108-e116. doi: 10.1016/j.wneu.2023.08.129. Epub 2023 Sep 9. PubMed 37690582 ↗
  • Lonjon M, Pennes F, Sedat J, Bataille B. Epidemiology, genetic, natural history and clinical presentation of giant cerebral aneurysms. Neurochirurgie. 2015 Dec;61(6):361-5. doi: 10.1016/j.neuchi.2015.08.003. Epub 2015 Dec 1. PubMed 26598391 ↗
  • Cagnazzo F, Mantilla D, Rouchaud A, Brinjikji W, Lefevre PH, Dargazanli C, Gascou G, Riquelme C, Perrini P, di Carlo D, Bonafe A, Costalat V. Endovascular Treatment of Very Large and Giant Intracranial Aneurysms: Comparison between Reconstructive and Deconstructive Techniques-A Meta-Analysis. AJNR Am J Neuroradiol. 2018 May;39(5):852-858. doi: 10.3174/ajnr.A5591. Epub 2018 Mar 15. PubMed 29545248 ↗

Individual participant data

Plan to share: Undecided — The researchers have not yet decided whether all IPD collected throughout the trial or only the IPD used in the results publication will be shared. Additionally, there is no URL available to share the results at this moment.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Jun 2025, 11 months after the start.

Of 67 non-industry observational studies under Intracranial Aneurysm, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 145. This study's planned 11 months is below that.

Counting every sponsor, half of 104 studies reached it within 46 months; a quarter within 36 and three quarters within 145.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 2, 2024
First posted
Aug 7, 2024
StartActual
Jul 17, 2024
Primary completionEst.
Jun 2025
CompletionEst.
Dec 2026
Last update
Aug 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06541275
Lead sponsor
National Centre for Neurosurgery, Republic of Kazakhstan
Responsible party
Karashash Menlibayeva (Head of the Hospital Management Department, National Centre for Neurosurgery, Republic of Kazakhstan) — Principal investigator
First posted
Aug 7, 2024
Start date
Jul 17, 2024
Primary completion
Jun 2025 (estimated)
Completion
Dec 2026 (estimated)
Last update
Aug 9, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion